Navigation Links
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Date:10/28/2008

Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio

FAIRFIELD, N.J., Oct. 28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a licensing agreement with Perrigo Company (Nasdaq: PRGO) for the U.S. marketing rights to Centany(R) Ointment and two prescription keratolytic brands. Patented through 2018, Centany(R) represents an important step in Medimetriks' plan to commercialize patent-protected therapies for the Dermatology and Podiatry markets that offer important patient benefits. Medimetriks plans to launch Centany(R) in early 2009, with the two additional products following shortly thereafter.

Previously marketed by Johnson & Johnson's OrthoNeutrogena professional division, Centany(R) is indicated for the topical treatment of impetigo due to Straphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. Centany(R) received a New Drug Approval in December of 2002 based in part on the unique properties of its vehicle, which offers important benefits over its competitors.

The two prescription keratolytic brands are urea-based therapies indicated for the treatment of severe dry skin. They are offered in delivery systems that are gaining wide acceptance in the Dermatology and Podiatry markets and are both patent pending. These new brands will compete in a skin softening market that approaches one million prescriptions annually.

"We are happy to have a partner that brings such a record of success in the branded pharmaceutical business," stated Sharon Kochan, Executive Vice President of Perrigo. "We believe the licensed products are in good hands given Medimetriks management's proven abilities in building a successful business in the Dermatology and Podiatry markets."

Medimetriks President and CEO, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio. Perrigo is known for developing high quality products and we believe these brands will benefit both our core Dermatology and Podiatry audiences and their patients."

Centany(R) is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of Centany(R): application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Please see full prescribing information.

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at http://www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
2. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
3. Perrigo Company Announces Appointment of New Board Member
4. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
5. Perrigo Announces Approval for Rx Cetirizine Syrup
6. Perrigo Confirms Filing for Generic Version of VANOS(R)
7. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
8. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
9. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
10. Perrigo Company Announces Quarterly Dividend
11. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... Rosa, CA (PRWEB) , ... June 25, 2017 , ... ... more green and growing foliage and plants, and along with that; a humdinger of ... sensitive allergy sufferers, it also means an increase in misery-causing grass and weed pollen. ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ ... Bayfront and Erie Convention Center on June 8-10. The weekend consisted of ... bowl, award and scholarship presentations, and professional networking. , On Friday June ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The ... will ultimately do significant harm to people with all chronic conditions, including mental ... it leaves in place the Affordable Care Act (ACA) requirement that insurers cover ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... cooking is essential, and two new videos highlight the importance of correctly using ... Christine Bruhn, Ph.D., who has done extensive research on consumer food safety habits. ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
(Date:5/26/2017)... International plc (NASDAQ: ENDP ) announced today that ... Company in a fireside chat at Goldman Sachs, 38 th ... at 10:40 a.m. PT / 1:40 p.m. ET. The conference ... Palos Verdes, CA. A live webcast ... the Company,s website at http://www.endo.com/investors/overview . Participants should allow ...
Breaking Medicine Technology: